Long-term Exon Skipping Studies With 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
Antisense-mediated exon skipping for Duchenne muscular dystrophy (DMD) is currently tested in phase 3 clinical trials. The aim of this approach is to modulate splicing by skipping a specific exon to reframe disrupted dystrophin transcripts, allowing the synthesis of a partly functional dystrophin pr...
Saved in:
Main Authors: | Christa L Tanganyika-de Winter (Author), Hans Heemskerk (Author), Tatyana G Karnaoukh (Author), Maaike van Putten (Author), Sjef J de Kimpe (Author), Judith van Deutekom (Author), Annemieke Aartsma-Rus (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2012-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
by: Silvana M G Jirka, et al.
Published: (2015) -
Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa
by: Jeroen Bremer, et al.
Published: (2016) -
Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP)
by: A Seda Yılmaz-Eliş, et al.
Published: (2013) -
Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
by: van Ommen Gert-Jan B, et al.
Published: (2007) -
Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
by: Maaike van Putten, et al.
Published: (2014)